.
Microscope in clinical setting

Urology & Uro-oncology Clinical Trials

The Trust is a member of the Kent Cancer Research Network and a major recruiter into clinical trials covering all types of cancer.

Clinical trials are now available locally for the majority of tumour types and referral pathways have been agreed across Trusts in Kent and Medway to maximise treatment opportunities for cancer patients. This involves testing new treatments as part of national trials.

Consultant Urological Surgeon Mr Sashi Kommu is Departmental Lead for Education, Research and Innovation and also leads the Clinical Trials undertaken by the Urology Team. He is Reader in Uro-oncology & Cancer Biology at the School of Biosciences, University of Kent. He is also the all-surgical specialty lead for The National Institute for Health Research (NIHR) Clinical Research Network for Kent, Surrey & Sussex.

If you would like further information on the research being carried out by Cancer Services please contact Sue Drakeley sue.drakeley@nhs.net.

The Urology Department has a faculty of experts comprising of Surgeons, Oncologists, Radiologists, Scientists, Research Fellows and Specialist Nurses and is actively involved in research and innovation.

Uro-oncology Studies

EKHUFT R&I

About Clinical Trials

NIHR Be Part of Research

WHO Clinical Trials Portal

ClinicalTrials.gov

UK Clinical Research Collaboration

University of Kent Biosciences Labs

NIHR Surgical Studies

Urology Trials/Studies open to recruitment are:

  • PIVOTAL Boost Trial - A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without  prostate boost
  • LEAP-0!1 – Commercial -Protocol Title: A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
 
  • MK -3475 -866 – Commercial -Protocol Title: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)  
  • MK-3475 -905 – Commercial - Protocol Title: A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)
  • Cassiope Study – Commercial - Prospective noninterventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy
  • UK Genetic Prostate Cancer study

Suspended/in hibernation

  • Add Aspirin - A phase III, double-blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
  • RAPPER study -Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy

EOIs

  • DASL-HiCAP - Darolutamide Augments Standard Therapy for Localized HighRisk Cancer of the Prostate (ANZUP1801). A randomized phase 3 trial of adding darolutamide to radiation and androgen deprivation therapy in high risk, clinically localized prostate cancer. 
  • ATLANTA - Study Title: Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment ( subject to Research Team capacity)
  • ONE-RCC- CANC44407 –– Commercial Observational study – patient reported outcomes and treatment experiences in Renal Cell Carcinoma (should be open in a few weeks.)
  • RAMPART - An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse (subject to Research Team Capacity)
Consultant Urology Researchers

Mr Ben Eddy
Mr Sashi S. Kommu
Mr Edward Steeter
Mr Milan Thomas
Mr Adrian Simoes

Consultant Uro-oncologists
Dr Carys Thomas
Dr Rakesh Raman
Dr Albert Edwards
Dr Patryk Brulinski

University Research Faculty
Professor Dan Mulvihill (Head of School)
Professor Michelle Garrett
Dr Tim Fenton
Mr Sashi S. Kommu
Professor Martin Michaelis
Dr Neil Kad
Dr Campbell Gourlay
Dr Jill Shepherd 
Dr Tobias Van der Haar
Dr Stuart Gibson
Dr Christopher Solomon

Research Facilitator
Jane Povey

Research Nurse
Pamela Offord

Uro-oncology Fellows
Davon Mitchell
Rasha Gendy